Insulin resistance and its role in the pathogenesis of type 2 diabetes

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 425-448

  Hawkins, Meredith ^a   Rossetti, Luciano ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971013807     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (444)

1. Rabinowitz D. Some endocrine and metabolic aspects of obesity. Annu Rev Med 1970;21:241-258.
2. Soeldner JS, Steinke J. Insulin resistance. Med Clin North Am 1965;49: 939-946.
3. Roth J, Kahn CR, Lesniak MA, et al. Receptors for insulin, NSILA-s, and growth hormone: applications to disease states in man. Recent Prog Horm Res 1975;31:95-139.
4. Folsom AR, Kushi LH, Anderson KE, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. Arch Intern Med 2000;160:2117-2128.
5. Chow W-H, Gridley G, Fraumeni JF, et al. Obesity, hypertension, and the risk of kidney cancer in men. . Engl J Med 2000;343:1305-1311.
6. Calle EE, Thun JM, Petrelli JM, et al. 1999. Body-mass index and mortality in a prospective cohort. . Engl J Med 1999;341:1097-1002.
7. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997;50:191-197.
8. Barrett-Connor EL. Obesity, atherosclerosis, and coronary artery disease. Ann Intern Med 1985;103:1010-1019.
9. O'Rahilly S. Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997;314:955-959.
10. Global Burden of Disease Estimate of 176,525,312 Individuals with Diabetes Mellitus in 2000. Data generated by World Health Organization and available at http://www.who.int/ncd/dia/databases4.htm
11. Warram JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic patients. Ann Intern Med 1990;113:909-915.
12. Lillioja S, Mott DM, Howard BV, et al. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. . Engl J Med 1988;318:1217-1225.
13. Haffner SM, Stern MP, Dunn J, et al. Diminished insulin sensitivity and increased insulin response in nonobese, nondiabetic Mexican Americans. Metabolism 1990;39:842-847.
14. Reaven GM, Bernstein R, Davis B, et al. Nonketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Med 1976;60:80-88.
15. DeFronzo RA. The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988;37:667-687.
16. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. . Engl J Med 1996;334: 952-957.
17. Reaven GM. Banting Lecture. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
19. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 16;287:356-359.
20. Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation 2003;108:1552-1553.
21. Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000;152:897-907.
22. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. . Clin Invest 1989;84:205-213.
23. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in noninsulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989;38: 387-395.
24. Kim SP, Ellmerer M, Van Citters GW, et al. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes 2003;52:2453-2460.
25. Ferrannini E, Galvan AQ, Gastaldelli A, et al. Insulin: new roles for an ancient hormone. Eur J Clin Invest 1999;29:842-852.
26. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
27. Bergman RN, Steil GM, Bradley DC, et al. Modeling of insulin action in vivo. Annu Rev Physiol 1992;54:861-883.
28. Cline GW, Petersen KF, Krssak M, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. . Engl J Med 1999;341:240-246.
29. Bruning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559-569.
30. Kim JK, Michael MD, Previs SF, et al. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. . Clin Invest 2000;105:1791-1797.
31. Okamoto H, Accili D. In vivo mutagenesis of the insulin receptor. . Biol Chem 2003;278:28359-28362.
32. Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 2000;6:924-928.
33. Wojtaszewski JF, Higaki Y, Hirshman MF, et al. Exercise modulates postreceptor insulin signaling and glucose transport in muscle-specific insulin receptor knockout mice . Clin Invest 1999;104:1257-1264.
34. Mu J, Brozinick JT Jr, Valladares O, et al. A role for AMP-activated protein kinase in contraction-and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 2001;7:1085-1094.
35. Shefi-Friedman L, Wertheimer E, Shen S, et al. Increased IGFR activity and glucose transport in cultured skeletal muscle from insulin receptor null mice. Am J Physiol Endocrinol Metab 2001;281:E16-E24.
36. Zierath JR, He L, Guma A, et al. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 1996;39:1180-1189.
37. Fernandez A, Kim J, Yakar S, et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001;15: 1926-1934.
38. Zierath JR, Wallberg-Henriksson H. From receptor to effector: insulin signal transduction in skeletal muscle from type II diabetic patients. Ann N Y Acad Sci 2002;967:120-134.
39. Goodyear LJ, Giorgino F, Sherman LA, et al. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. . Clin Invest 1995;95:2195-2204.
40. Bjornholm M, Kawano Y, Lehtihet M, et al. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 1997;46: 524-527.
41. Zierath JR, Krook A, Wallberg-Henriksson H. Insulin action in skeletal muscle from patients with NIDDM. Mol Cell Biochem 1998;182:153-160.
42. Zierath JR, Galuska D, Nolte LA, et al. Effects of glycemia on glucose transport in isolated skeletal muscle from patients with NIDDM: in vitro reversal of muscular insulin resistance. Diabetologia 1994;37:270-277.
43. Krutzfeldt J, Kausch C, Volk A, et al. Insulin signaling and action in cultured skeletal muscle cells from lean healthy humans with high and low insulin sensitivity. Diabetes 2000;49:992-998.
44. Maddux BA, Sbraccia P, Kumakura S, et al. Membrane glycoprotein PC-1 in the insulin resistance of non-insulin dependent diabetes mellitus. Nature 1995;373:448-451.
45. Goldfine ID, Maddux BA, Youngren JF, et al. Membrane glycoprotein PC-1 and insulin resistance. Mol Cell Biochem 1998;182:177-184.
46. Frittitta L, Spampinato D, Solini A, et al. Elevated PC-1 content in cultured skin fibroblasts correlates with decreased in vivo and in vitro insulin action in nondiabetic subjects: Evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes 1998;47:1095-1100.
47. Kumakura S, Maddux BA, Sung CK. Overexpression of membrane glycoprotein PC-1 can influence insulin action at a post-receptor site. . Cell Biochem 1998;3:366-377.
48. Youngren JF, Maddux BA, Sasson S, et al. Skeletal muscle content of membrane glycoprotein pc-1 in obesity: relationship to muscle glucose transport. Diabetes 1996;10:1324-1328.
49. Urano T, Emkey R, Feig LA. Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J 1996;15:810-816.
50. Ahmad F, Azevedo J, Cortright R, et al. Alterations in skeletal muscle proteintyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. . Clin Invest 1997;100:449-458.
51. Goldstein BJ, Ahmad F, Ding W, et al. Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. Mol Cell Biochem 1998; 182:91-99.
52. Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1b gene. Science 1999;283:1544-1548.
53. Zinker BA, Rondinone CM, Trevillyan JM, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A 2002;99: 11357-11362.
54. Wagner JA. Early clinical development of pharmaceuticals for type 2 diabetes mellitus: from preclinical models to human investigation. . Clin Endocrinol Metab 2002;87:5362-5366.
55. Campbell PJ, Carlson MG, Nurjhan N. Fat metabolism in human obesity. Am J Physiol 1994;266:E600-E605.
56. Jensen MD, Haymond MW, Rizza RA, et al. Influence of body fat distribution on free fatty acid metabolism in obesity. . Clin Invest 1989;83:1168-1173.
57. Groop LC, Saloranta C, Shank M, et al. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulindependent diabetes mellitus. . Clin Endocrinol Metab 1991;72:96-107.
58. Eriksson JW, Smith U, Waagstein F, et al. Glucose turnover and adipose tissue lipolysis are insulin-resistant in healthy relatives of type 2 diabetes patients: is cellular insulin resistance a secondary phenomenon? Diabetes 1999; 48:1572-1578.
59. Gelding SV, Coldham N, Niththyananthan R, et al. Insulin resistance with respect to lipolysis in non-diabetic relatives of European patients with type 2 diabetes. Diabet Med 1995;12:66-73.
60. Groop LC, Bonadonna RC, Simonson DC, et al. Effect of insulin on oxidative and nonoxidative pathways of free fatty acid metabolism in human obesity. Am J Physiol 1992;263:E79-E84.
61. Bjorntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover rate in obesity. Acta Med Scand 1969;185:351-356.
62. Abbasi F, McLaughlin T, Lamendola C, et al. Insulin regulation of plasma free fatty acid concentrations is abnormal in healthy subjects with muscle insulin resistance. Metabolism 2000;49:151-154.
63. Bluher M, Michael MD, Peroni OD, et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 2002;3:25-38.
64. Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001;409:729-733.
65. Uysal KT, Scheja L, Wiesbrock SM, et al. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000;141: 3388-3396.
66. Shepherd PR, Gnudi L, Tozzo E, et al. 1 Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. . Biol Chem 1993;268:22243-22246.
67. Tozzo E, Gnudi L, Kahn BB. Amelioration of insulin resistance in streptozotocin diabetic mice by transgenic overexpression of GLUT4 driven by an adipose-specific promoter. Endocrinology 1997;138:1604-1611.
68. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 1999;48:1198-1214.
69. Ader M, Bergman RN. Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. Am J Physiol 1990;245:E1020-E1032.
70. Giacca A, Fisher SJ, Shi ZO, et al. Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs. . Clin Invest 1992;90:1769-1777.
71. Mittelman SD, Fu YY, Rebrin K, et al. Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia. . Clin Invest 1997;100:3121-3130.
72. Sindelar DK, Balcom JH, Chu CA, et al. A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog. Diabetes 1996;45:1594-1605.
73. Sindelar DK, Chu CA, Rohlie M, et al. The role of fatty acids in mediating the effects of peripheral insulin on hepatic glucose production in the conscious dog. Diabetes 1997;46:187-196.
74. Saloranta C, Taskinen M, Widen E, et al. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 1993;42:1559-1566.
75. Lauro D, Kido Y, Castle AL, et al. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue. Nat Genet 1998;20:294-298.
76. Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000;6:87-97.
77. Fisher SJ, Kahn CR. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. . Clin Invest 2003;111:463-468.
78. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978;272:827-829.
79. Porte D Jr, Seeley RJ, Woods SC, et al. Obesity, diabetes and the central nervous system. Diabetologia 1998;41:863-881.
80. Leloup C, Arluison M, Kassis N, et al. Discrete brain areas express the insulin-responsive glucose transporter GLUT4. Brain Res Mol Brain Res 1996;38:45-53.
81. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289:2122-2155.
82. Obici S, Feng Z, Karkanias G, et al. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 2002; 5:566-572.
83. Obici S, Zhang BB, Karkanias G, et al. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002;8:1376-1382.
84. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 2002;113[Suppl 6A]:3S-11S.
85. Rubinstein H, Zimmet P. Phosphate, wealth, and health in Nauru: a study of lifestyle change. Brolga: Gundaroo, 1993.
86. Knowler W, Pettitt D, Saad M, et al. Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diabetes Metab Rev 1990;6:1-27.
87. Diamond J. The double puzzle of diabetes. Nature 2003;423:599-602.
88. Hales C, Barker D. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992;35:595-601.
89. O'Rahilly S, Farooqi IS, Yeo GS, et al. Minireview: human obesity-lessons from monogenic disorders [review]. Endocrinology 2003;144:3757-3764.
90. Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol 2002;147:1096-1101.
91. Taylor SI. Insulin action, insulin resistance, and type 2 diabetes mellitus. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic and molecular bases of inherited disease, 8th ed. New York; McGraw-Hill, 2000:1433-1470.
92. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. . Clin Invest 1999; 103:931-943.
93. Krook A, Brueton L, O'Rahilly S. Homozygous nonsense mutation in the insulin receptor gene in infant with leprechaunism. Lancet 1993;342: 277-278.
94. Taylor SI, Accili D, Cama A, et al. Mutations in the insulin receptor gene in patients with genetic syndromes of insulin resistance. Adv Exp Med Biol 1991;293:197-213.
95. Donohue LW, Uchida I. Leprechaunism. Aeuphemism for a rare familial disorder. . Pediatr 1954;45:505-519.
96. Longo N, Wang Y, Smith SA, et al. Genotype-phenotype correlation in inherited severe insulin resistance. Hum Mol Genet 2002;11:1465-1475.
97. Moller DE, Yakota A, White MF, et al. A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance. . Biol Chem 1990;265: 14979-14985.
98. Taylor SI, Accili D, Haft CR, et al. Mechanisms of hormone resistance: lessons from insulin-resistant patients. Acta Paediatr Suppl 1994;399:95-104.
99. Kadowaki T, Kadowaki H, Rechler MM, et al. Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance. . Clin Invest 1990;86:254-264.
100. Fradkin JE, Eastman RC, Lesniak MA, et al. Specificity spillover at the hormone receptor-exploring its role in human disease. . Engl J Med 1989; 320:640-645.
101. Kuzuya H, Matsuura N, Sakamoto M, et al. Trial of insulin-like growth factor 1 therapy for patients with extreme insulin resistance syndromes. Diabetes 1993;42:696-705.
102. Nakae J, Kato M, Murashita M, et al. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. . Clin Endocrinol Metab 1998;83:542-549.
103. Flier JS, Moller DE, Moses AC, et al. Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. . Clin Endocrinol Metab 1993;76:1533-1541.
104. Dib K, Whitehead JP, Humphreys PJ, et al. Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance. . Clin Invest 1998;101:1111-1120.
105. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR2, a lipid-activated transcription factor. Cell 1994;79:1147-1156.
106. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999;16:179-192.
107. Maeda N, Takahashi M, Funahashi T, et al. PPAR ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-2099.
108. Barroso I, Gurnell M, Crowley VEF, et al. Dominant negative mutations in human PPAR are associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880-883.
109. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gene in a patient with familial partial lipodystrophy. . Clin Endocrinol Metab 2002;87:408-411.
110. Hegele RA, Henian C, Frankowski C, et al. PPARG F388L, a transactivationdeficient mutant, in familial partial lipodystrophy. Diabetes 2002;51: 3586-3590.
111. Gurnell M. PPARgamma and metabolism: insights from the study of human genetic variants. Clin Endocrinol 2003;59:267-277.
112. Savage DB, Tan GD, Acerini CL, et al. The human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptors and PPAR. Diabetes 2003;52:910-917.
113. Ristow M, Muller-Wieland D, Pfeiffer A, et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. . Engl J Med 1998;339:953-959.
114. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPAR2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
115. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPAR Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Gen 2000;26:76-80.
116. Werman A, Hollenberg A, Solanes G, et al. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. . Biol Chem 1997;272:20230-20235.
117. Masud S, Ye S; SAS Group. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. . Med Genet 2003;40:773-780.
118. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. . Clin Invest 1997;99:2416-2422.
119. Luan J, Browne PO, Harding AH, et al. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 2001;50:686-689.
120. Dunnigan MG, Cochrane MA, Kelly A, et al., Familial lipoatrophic diabetes with dominant transmission: a new syndrome. . J Med 1974;43:33-48.
121. Garg A, Peshock RM, Fleckenstein JL, et al. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). . Clin Endocrinol Metab 1999;84:170-174.
122. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 1999; 276(5 Pt 1):E977-E989.
123. Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 2000;9:109-112.
124. Shackleton S Lloyd DJ, Jackson SN, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 2000;24:153-156.
125. Hegele RA. Molecular basis of partial lipodystrophy and prospects for therapy. Trends Mol Med 2001;7:121-126.
126. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl 1996;413:2-28.
127. Agarwal AK, Arioglu E, De Almeida S, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 2002; 31:21-32.
128. Magre J, Delepine M, Khallouf E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 2001;28:365-370.
129. Hansen T, Andersen CB, Echwald SM, et al. Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index. Diabetes 1997;46: 494-501.
130. Clausen JO, Hansen T, Bjorbaek C, et al. Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet 1995;346:397-402.
131. Almind K, Inoue G, Pedersen O, et al. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. . Clin Invest 1996;97:2569-2575.
132. Ura S, Araki E, Kishikawa H, et al. Molecular scanning of the insulin receptor substrate-1 (IRS-1) gene in Japanese patients with NIDDM: identification of five novel polymorphisms. Diabetologia 1996;39:600-608.
133. Kissebah AH, Sonnenberg G, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A 2000;97:14478-14483.
134. Vionnet N, Hani El H, Dupont S, et al. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000;67:1470-1480.
135. Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 2000;24: 861-868.
136. Savage DB, Agostini M, Barroso I, et al. Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 2002;31:379-384.
137. Bruning JC, Winnay J, Bonner-Weir S, et al. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 1997;88:561-572.
138. Ghosh S, Collins FS. The geneticist's approach to complex disease. Annu Rev Med 1996;47:333-353.
139. Kido Y, Burks DJ, Withers D, et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. . Clin Invest 2000;105:199-205.
140. Kido Y, Philippe N, Schaffer AA, et al. Genetic modifiers of the insulin resistance phenotype in mice. Diabetes 2000;49:589-596.
141. Eaton SB, Konner M, Shostak M. Stone agers in the fast lane: chronic degenerative diseases in evolutionary perspective. Am J Med 1988;84:739-749.
142. Neel JV. Diabetes mellitus a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 1962;14:352-353.
143. Chakravarthy M, Booth FW. Eating, exercise, and "thrifty" genotypes: connecting the dots toward an evolutionary understanding of modern chronic diseases. . Appl Physiol 2004;96:3-10.
144. Desai M, Crowther NJ, Ozanne SE, et al. Adult glucose and lipid metabolism may be programmed during fetal life [review]. Biochem Soc Trans 1995;23: 331-335.
145. Ozanne SE. Metabolic programming in animals. BMJ 2001;60:143-152.
146. Ozanne SE, Wang CL, Coleman N, et al. Altered muscle insulin sensitivity in the male offspring of protein-malnourished rats. Am J Physiol 1996;271(6 Pt 1): E1128-E1134.
147. Ozanne SE, Smith GD, Tikerpae J, et al. Altered regulation of hepatic glucose output in the male offspring of protein-malnourished rat dams. Am J Physiol 1996;270(4 Pt 1):E559-E564.
148. Ozanne SE, Nave BT, Wang CL, et al. Poor fetal nutrition causes long-term changes in expression of insulin signaling components in adipocytes. Am J Physiol 1997;273(1 Pt 1):E46-E51.
149. Ozanne SE, Hales CN. The long-term consequences of intra-uterine protein malnutrition for glucose metabolism. Proc Nutr Soc 1999;58:615-619.
150. Hales CN, Desai M, Ozanne SE. The thrifty phenotype hypothesis: how does it look after 5 years? Diabet Med 1997;14:189-195.
151. Reitman ML, Arioglu E, Gavrilova O, et al. Lipoatrophy revisited. Trends Endocrinol Metab 2000;11:410-416.
152. Comuzzie AG, Allison DB. The search for human obesity genes. Science 1998;280:1374-1377.
153. Hill JO, Peters JC. Environmental contributions to the obesity epidemic. Science 1998;280:1371-1374.
154. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47.
155. McCrory MA, Fuss PJ, Hays NP, et al. Overeating in America. Association between restaurant food consumption and body fatness in healthy adult men and women ages 19 to 80. Obes Res 1999;7:564-571.
156. Popkin BM, Nielsen SJ. The sweetening of the world's diet. Obes Res 2003;11:1325-1332.
157. Nielsen SJ, Siega-Riz AM, Popkin BM. Trends in energy intake in U.S. between 1977 and 1996: similar shifts seen across age groups. Obes Res 2002;10:370-378.
158. Popkin BM. The nutrition transition and obesity in the developing world. . Nutr 2001;131:871S-873S.
159. Drewnowski A, Popkin BM. The nutrition transition: new trends in the global diet. Nutr Rev 1997;55:31-43.
160. Popkin BM. Urbanization, lifestyle changes and the nutrition transition. World Dev 1999;27:1905-1916.
161. Monteiro CA, D'A Benicio MH, Conde WL, et al. Shifting obesity trends in Brazil. Eur J Clin Nutr 2000;54:342-346.
162. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002;13:51-59.
163. Rajala MW, Scherer PE. Minireview: the adipocyte: at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003;144:3765-3773.
164. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. . Biol Chem 1995;270:26746-26749.
165. Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 2003;3:207-213.
166. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adiposespecific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-1599.
167. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-1133.
168. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. . Clin Endocrinol Metab 2001;86:1930-1935.
169. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257: 79-83.
170. Combs TP, Berg AH, Rajala MW, et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 2003;52:268-276.
171. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. . Clin Endocrinol Metab 2001;86:3815-3819.
172. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226-228.
173. Berg AH, Combs T, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-953.
174. Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. . Clin Invest 2001;108:1875-1881.
175. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 20028:1288-1295.
176. Combs TP, Pajvani UB, Berg AH, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004;145: 367-383.
177. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-737.
178. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. . Biol Chem 2002;277: 25863-25866.
179. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin: implications for metabolic regulation and bioactivity. . Biol Chem 2003;278:9073-9085.
180. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. . Biol Chem. 2004;279:12152-12162.
181. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
182. Sivitz WI, Walsh SA, Morgan DA, et al. Effects of leptin on insulin sensitivity in normal rats. Endocrinology 1997;138:3395-3401.
183. Rossetti L, Massillon D, Barzilai N, et al. Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. . Biol Chem 1997;272:27758-27763.
184. Barzilai N, Wang J, Massilon D, et al. Leptin selectively decreases visceral adiposity and enhances insulin action. . Clin Invest 1997;100:3105-3110.
185. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343.
186. Minokoshi Y, Kahn BB. Role of AMP-activated protein kinase in leptininduced fatty acid oxidation in muscle. Biochem Soc Trans 2003;31:196-201.
187. Huang L, Li C. Leptin: a multifunctional hormone. Cell Res 2000;10:81-92.
188. Lord GM, Matarese G, Howard JK, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998;394:897-901.
189. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. . Clin Invest 2002;110:1093-1103.
190. Popovic V, Damjanovic S, Dieguez C, et al. Leptin and the pituitary. Pituitary 2001;4:7-14.
191. Hukshorn CJ, van Dielen FM, Buurman WA, et al. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord 2002;26:504-509.
192. Wang J, Obici S, Morgan K, et al. Overfeeding rapidly induces leptin and insulin resistance. Diabetes 2001;50:2786-2791.
193. Rosenbaum M, Murphy EM, Heymsfield SB, et al. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. . Clin Endocrinol Metab 2002;87:2391-2394.
194. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
195. Rajala MW, Obici S, Scherer PE, et al. Adipose-derived resistin and gutderived resistin-like molecule-D'selectively impair insulin action on glucose production. . Clin Invest 2003;111:225-230.
196. Way JM, Gorgun CZ, Tong Q, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferatoractivated receptor agonists. . Biol Chem 2001;276:25651-25653.
197. Janke J, Engeli S, Gorzelniak K, et al. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002;10:1-5.
198. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR activators. Biochem Biophys Res Commun 2003 300:472-476.
199. Fain JN, Cheema PS, Bahouth SW, et al. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 2003;300: 674-678.
200. McTernan CL, McTernan PG, Harte AL, et al. Resistin, central obesity, and type 2 diabetes. Lancet 2002;359:46-47.
201. McTernan PG, McTernan CL, Chetty R, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. . Clin Endocrinol Metab 2002;87:2407.
202. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE., et al. Serum resistin (FIZZ3) protein is increased in obese humans. . Clin Endocrinol Metab 2003;88: 5452-5455.
203. Lee JH, Chan JL, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. . Clin Endocrinol Metab 2003;88:4848-4856.
204. Lee H, Chan JL, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003;88:4848-4856.
205. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001;50:2199-2202.
206. Combs TP, Berg AH, Rajala MW, et al. Sexual differentiation, pregnancy, calorie restriction and aging affect the adipocyte-specific secretory protein Acrp30/adiponectin. Diabetes 2003;52:268-276.
207. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241-1248.
208. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002;5:551-559.
209. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-1292.
210. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47.
211. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
212. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. . Clin Endocrinol Metab 1997;82:1313-1316.
213. Samad F, Yamamoto K, Pandey M, et al. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med 1997;3:37-48.
214. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-2135.
215. Weyer C, Yudkin JS, Stehouwer CD, et al. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002;161:233-242.
216. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003;100:7265-7270.
217. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
218. Borst SE, Bagby GJ. Neutralization of tumor necrosis factor reverses ageinduced impairment of insulin responsiveness in skeletal muscle of Sprague-Dawley rats. Metabolism 2002;51:1061-1064.
219. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389: 610-614.
220. Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology 1998;139:4832-4838.
221. Hotamisligil GS, Murray DL, Choy LN, et al. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 1994;91: 4854-4858.
222. Zhang HH, Halbleib M, Ahmad F, et al. Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 2002;51:2929-2935.
223. Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology 1998;139:4832-4838.
224. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000;11:212-217.
225. Ofei F, Hurel S, Newkirk J, et al. Effects of an engineered human anti-TNFalpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-885.
226. Zandi E, Rothward DM, Delhase M, et al. The IB kinase complex (IKK) contains two kinase subunits, IKK and IKKD, necessary for IB phosphorylation and NF-B activation. Cell 1997;91:243-252.
227. Nonogaki K, Fuller GM, Furetes NL, et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995;136:2143-2149.
228. Senn JJ, Klover PJ, Nowak IA, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002;51:3391-3399.
229. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003;100:7265-7270.
230. Baron SH. Salicylates as hypoglycemic agents. Diabetes Care 1982;5:64-71.
231. Yin M-J, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IB kinase-_. Nature 1998;396:77-80.
232. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and dietinduced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293:1673-1677.
233. Hundal RS. Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. . Clin Invest 2002;109:1321-1326.
234. Gao Z, Zuberi A, Quon MJ, et al. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. . Biol Chem 2003;278:24944-24950.
235. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. . Clin Invest 2002;109:1321-1326.
236. Xu H, Barnes GT, Yang O, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. . Clin Invest 2003;112:1821-1830.
237. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. . Clin Invest 2003;112: 1796-1808.
238. Moraes RC, Blondet A, Birkenkamp-Demtroeder K, et al. Study of the alteration of gene expression in adipose tissue of diet-induced obese mice by microarray and reverse transcription-polymerase chain reaction analyses. Endocrinology 2003;144:4773-4782.
239. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998;281:1683-1686.
240. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-737.
241. Levine JA, Jensen MD, Eberhardt NL, et al. Adipocyte macrophage colonystimulating factor is a mediator of adipose tissue growth. . Clin Invest 1998;101:1557-1564.
242. Schneider BS, Faust IM, Hemmes R, et al. Effects of altered adipose tissue morphology on plasma insulin levels in the rat. Am J Physiol 1981;240:E358-E362.
243. Weyer C, Wolford JK, Hansen RL, et al. Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21-q23 and is associated with a common polymorphism in LMNA in Pima Indians. Mol Genet Metab 2001;72:231-238.
244. Weyer C, Foley JE, Bogardus C, et al. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 2000;43:1498-1506.
245. Stern JS, Batchelor BR, Hollander N, et al. Adipose-cell size and immunoreactive insulin levels in obese and normal-weight adults. Lancet 1972;2: 948-951.
246. Hissin PJ, Foley JE, Wardzala LJ, et al. Mechanism of insulin-resistant glucose transport activity in the enlarged adipose cell of the aged, obese rat. . Clin Invest 1982;70:780-790.
247. Le Lay S, Kried S, Farnier C, et al. Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes. . Biol Chem 2001;276:16904-16910.
248. Friedman JM. Obesity in the new millennium. Nature 2000;404:632-634.
249. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
250. Stolk RP, Meijer R, Mali WP, et al. Ultrasound measurements of intraabdominal fat estimate the metabolic syndrome better than do measurements of waist circumference. Am J Clin Nutr 2003;77:857-860.
251. DiPietro L, Katz LD, Nadel ER. Excess abdominal adiposity remains correlated with altered lipid concentrations in healthy older women. Int J Obes Relat Metab Disord 1999;23:432-436.
252. Abate N, Garg A, Peshock RM, et al. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 1996;45:1684-1693.
253. Kahn BB, Flier JS. Obesity and insulin resistance. . Clin Invest 2000;106: 473-481.
254. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-229.
255. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000;49:883-888.
256. Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin. and rosiglitazone. . Clin Endocrinol Metab 2002;87:5662-5667.
257. Staiger H, Tschritter O, Machann J, et al. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 2003;11:368-372.
258. Milan G, Granzotto M, Scarda A, et al. Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res 2002;10:1095-1103.
259. Barzilai N, She L, Liu BQ, et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999;48:94-98.
260. Gabriely I, Ma XH, Yang XM, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 2002;51:2951-2958.
261. Lawrence RD. Lipodystrophy and hepatomegaly with diabetes, lipaemia, and other metabolic disturbances: a case throwing new light on the action of insulin. Lancet 1946;724-731, 773-775.
262. Hubler A, Abendroth K, Keiner T, et al. Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence syndrome) connected with autoantibodies against adipocyte membranes. Exp Clin Endocrinol Diabetes 1998;106:79-84.
263. Spranger A, Spranger M, Tasman AJ, et al. Barraquer-Simons syndrome (with sensorineural deafness): a contribution to the differential diagnosis of lipodystrophy syndromes. Am J Med Genet 1997;71:397-400.
264. Barbaro G. HIV-associated lipodystrophy: pathogenesis and clinical features. Adv Cardiol 2003;40:97-104.
265. Kino T, Mirani M, Alesci S, et al. AIDS-related lipodystrophy/insulin resistance syndrome. Horm Metab Res 2003;35:129-136.
266. Zhang B, MacNaul K, Szalkowski D, et al. Inhibition of adipocyte differentiation by HIV protease inhibitors. J. Clin Endocrinol Metab 1999;84:4274-4277.
267. Madge S, Kinloch-de-Loes S, Mercey D, et al. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999;13:735-737.
268. Garg A. Lipodystrophies. Am J Med 2000;108:143-152.
269. Burant CF, Sreenan S, Hirano K, et al. Troglitazone action is independent of adipose tissue. . Clin Invest 1997;100:2900-2908.
270. Moitra J, Mason MM, Olive M, et al. Life without white fat: a transgenic mouse. Genes Dev 1998;12:3168-3181.
271. Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998;12: 3182-3194.
272. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-770.
273. Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A 1997;94: 4637-4641.
274. Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73-76.
275. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. . Engl J Med 2002;346:570-578.
276. Gavrilova O, Marcus-Samuels D, Leon LR, et al. Leptin and diabetes in lipoatrophic mice. Nature 2000;403:850.
277. Kulkarni RN, Wang ZL, Wang RM, et al. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. . Clin Invest 1997;100:2729-2736.
278. Kieffer TJ, Habener JF. The adipoinsular axis: Effects of leptin on pancreatic D-cells. Am J Physiol Endocrinol Metab 2000;278:E1-E14.
279. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. . Clin Invest 2000;105: 271-278.
280. Kim JK, Gavrilova O, Chen Y, et al. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. . Biol Chem 2000;275:8456-8460.
281. Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73-76.
282. Gavrilova O, Marcus-Samuels B, Leon L.R, et al. Leptin and diabetes in lipoatrophic mice. Nature 2000;403:850-851.
283. Ebihara K, Ogawa Y, Masuzaki H, et al. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 2001;50:1440-1448.
284. Colombo C, Cutson JJ, Yamauchi T, et al. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 2002;51:2727-2733.
285. Laustsen PG, Michael MD, Crute BE, et al. Lipoatrophic diabetes in Irs1(-/-)/ Irs3(-/-) double knockout mice. Genes Dev 2002;16:3213-3222.
286. Reitman ML, Arioglu E, Gavrilova O, et al. Lipoatrophy revisited. Trends Endocrinol Metab 2000;11:410-416.
287. Robinson C, Tamborlane WV, Maggs DG, et al. Effect of insulin on glycerol production in obese adolescents. Am J Physiol 1998;274:E737-E743.
288. Phillips DI, Caddy S, Ilic V, et al. Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism 1996;45:947-950.
289. Goodpaster BH, Thaete FL, Simoneau JA, et al. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997;46:1579-1585.
290. Pan DA, Lillioja S, Kriketos AD, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997;46:983-988.
291. Schick F, Machann J, Brechtel K, et al. MRI of muscular fat. Magn Reson Med 2002;47:720-727.
292. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 1999; 276:E977-E989.
293. Sinha R, Dufour S, Petersen KF, et al. Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 2002;51:1022-1027.
294. Kelley DE, Goodpaster B, Wing RR, et al. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 1999;277:E1130-E1141.
295. Simoneau JA, Veerkamp JH, Turcotte LP, et al. Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J 1999;13:2051-2060.
296. Kim JY, Hickner RC, Cortright RL, et al. Lipid oxidation is reduced in obese human skeletal muscle. Am J Physiol Endocrinol Metab 2000;279:E1039-E1044.
297. Dobbins RL, Szczepaniak LS, Bentley B, et al. Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 2001;50:123-130.
298. Sidossis LS, Mittendorfer B, Chinkes D, et al. Effect of hyperglycemiahyperinsulinemia on whole body and regional fatty acid metabolism. Am J Physiol 276:E427-E434.
299. Sidossis LS, Stuart CA, Shulman GI, et al. Glucose plus insulin regulate fat oxidation by controlling the rate of fatty acid entry into the mitochondria. . Clin Invest 1999;98:2244-2250.
300. Sidossis LS, Wolfe RR. Glucose and insulin-induced inhibition of fatty acid oxidation: the glucose-fatty acid cycle reversed. Am J Physiol 1996;270:E733-E738.
301. McGarry JD, Mannaerts GP, Foster DW. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. . Clin Invest 1977;60:265-270.
302. Saha AK, Kurowski TG, Ruderman NB. A malonyl-CoA fuel-sensing mechanism in muscle: effects of insulin, glucose, and denervation. Am J Physiol 1995;269:E283-E289.
303. Boden G, Lebed B, Schatz M, et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001;50:1612-1617.
304. Oakes ND, Bell KS, Furler SM, et al. Diet-induced muscle insulin resistance in rats is ameliorated by acute dietary lipid withdrawal or a single bout of exercise: parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acyl-CoA. Diabetes 1997;46:2022-2028.
305. Kelley DE, Goodpaster BH. Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. Diabetes Care 2001;24:933-941.
306. Hoppeler H, Billeter R, Horvath PJ, et al. Muscle structure with low-and high-fat diets in well-trained male runners. Int J Sports Med 1999;20:522-526.
307. Haap M, Thamer C, Machann J, et al. Metabolic characterization of a woman homozygous for the ser113leu missense mutation in carnitine palmitoyl transferase II. . Clin Endocrinol Metab 2002;87:2139-2143.
308. Anderwald C, Bernroider E, Krssak M, et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 2002;51:3025-3032.
309. Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003;100: 3077-3082.
310. Ruderman NB, Saha AK, Vavvas D, et al. Malonyl-coA, fuel sensing, and insulin resistance. Am J Physiol Endocrinol Metab 1999;276:E1-E18.
311. Prentki M, Corkey BE. Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 1996;45:273-283.
312. Ruderman NB, Saha AK, Vavvas DJ, et al. Lipid abnormalities in muscle of insulin-resistant rodents. The malonyl CoA hypothesis. Ann N Y Acad Sci 1997;827:221-230.
313. Wititsuwannakul D, Kim K-H. Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase. . Biol Chem 1977;252:7812-7817.
314. Sleeman MW, Donegan NP, Heller-Harrison R, et al. Association of acyl-CoA synthetase-1 with GLUT4-containing vesicles. . Biol Chem 1998;273:3132-3135.
315. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. . Clin Endocrinol Metab 1999;84:1513-1517.
316. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-438.
317. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
318. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116: 1413-1419.
319. Thomsen C, Becker U, Winkler K, et al. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994;12:487-495.
320. Longo R, Ricci C, Masutti F, et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993;28:297-302.
321. Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. . Clin Endocrinol Metab 2002;87:3019-3022.
322. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
323. Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-758.
324. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
325. Seppälä-Lindroos A, Vehkavaara S, Häkkinen A-M, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. . Clin Endocrinol Metab 2002;87:3023-3028.
326. Kelley DE, McKolanis TM, Hegazi RAF, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285: E906-E916.
327. Hwang JH, Hawkins M, Stein D, et al. Simultaneous measurement of intrahepatic, intramyocellular and visceral fat content by in vivo magnetic resonance methods: relation to insulin sensitivity. In: Proceedings of the International Society of Magnetic Resonance in Medicine, 2004;11:P503.
328. An J, Shiota M, Newgard C. Amelioration of muscle insulin resistance by activation of fat oxidation in liver. Diabetes 2003;52[Suppl 1]:296.
329. Petersen KF, Tygstrup N. A liver factor increasing glucose uptake in rat hindquarters. . Hepatol 1994;20:461-465.
330. Flier JS, Kahn CR, Jarrett DB, et al. The immunology of the insulin receptor. Immunol Commun 1976;5:361-373.
331. Flier JS. Lilly Lecture: syndromes of insulin resistance. From patient to gene and back again. Diabetes 1992;41:1207-1219.
332. Taylor SI, Accili D, Haft CR, et al. Mechanisms of hormone resistance: lessons from insulin-resistant patients. Acta Paediatr Suppl 1994;399:95-104.
333. Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int Suppl 1997;62:S48-S52.
334. Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992;61:377-382.
335. Schmitz O, Orskov L, Lund S, et al. Glucose metabolism in chronic renal failure with reference to GH treatment of uremic children. . Pediatr Endocrinol 1993;6:53-59.
336. Farrer M, Fulcher GR, Johnson AJ, et al. Effect of acute inhibition of lipolysis on operation of the glucose-fatty acid cycle in hepatic cirrhosis. Metabolism 1992;41:465-470.
337. Taylor R, Heine RJ, Collins J, et al. Insulin action in cirrhosis. Hepatology 1985; 5:64-71.
338. Rowe JW, Wands JR, Mezey E, et al. Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred. Medicine (Baltimore) 1977; 56:197-211.
339. Hramiak IM, Finegood DT, Adams PC. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med 1997;20:110-118.
340. Fernandez-Real JM, Penarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002;51:1000-1004.
341. Pappas S, Donohue SM, Denver AE, et al. Glucose intolerance in thalassemia major is related to insulin resistance and hepatic dysfunction. Metabolism 1996;45:652-657.
342. Copeland GP, Leinster SJ, Davis JC, et al. Insulin resistance in patients with colorectal cancer. Br J Surg 1987;74:1031-1035.
343. Isaksson B, Strommer L, Friess H, et al. Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients. Pancreas 2003;26:173-177.
344. McCall JL, Tuckey JA, Parry BR. Serum tumour necrosis factor alpha and insulin resistance in gastrointestinal cancer. Br J Surg 1992;79:1361-1363.
345. Makino T, Noguchi Y, Yoshikawa T, et al. Circulating interleukin 6 concentrations and insulin resistance in patients with cancer. Br J Surg 1998;85: 1658-1662.
346. Noguchi Y, Yoshikawa T, Marat D, et al. Insulin resistance in cancer patients is associated with enhanced tumor necrosis factor-alpha expression in skeletal muscle. Biochem Biophys Res Commun 1998;253:887-892.
347. Koopmans SJ, Ohman L, Haywood JR, et al. Seven days of euglycemic hyperinsulinemia induces insulin resistance for glucose metabolism but not hypertension, elevated catecholamine levels, or increased sodium retention in conscious normal rats. Diabetes 1997;46:1572-1578.
348. Del Prato S, Riccio A, Vigili de Kreutzenberg S, et al. Mechanisms of fasting hypoglycemia and concomitant insulin resistance in insulinoma patients. Metabolism 1993;42:24-29.
349. Hjollund E, Pedersen O, Richelsen B, et al. Glucose transport and metabolism in adipocytes from newly diagnosed untreated insulin-dependent diabetics. Severely impaired basal and postinsulin binding activities. . Clin Invest 1985;76:2091-2096.
350. Pedersen O, Hjollund E. Insulin receptor binding to fat and blood cells and insulin action in fat cells from insulin-dependent diabetics. Diabetes 1982; 31:706-715.
351. Hurrell DG, Pedersen O, Kahn CR. Alterations in the hepatic insulin receptor kinase in genetic and acquired obesity in rats. Endocrinology 1989; 125:2454-2462.
352. Freidenberg GR, Reichart DR, Olefsky JM, et al. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss. . Clin Invest 1988;82:1398-1406.
353. Gerich JE. Lilly Lecture 1988. Glucose counterregulation and its impact on diabetes mellitus. Diabetes 1988;37:1608-1617.
354. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. . Clin Endocrinol Metab 1982;54:131-138.
355. Karnieli E, Cohen P, Barzilai N, et al. Insulin resistance in Cushing's syndrome. Horm Metab Res 1985;17:518-521.
356. Bjorntorp P, Rosmond R. The metabolic syndrome-a neuroendocrine disorder? Br J Nutr 2000;83[Suppl 1]:S49-S57.
357. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. . Engl J Med 1996;334:374-381.
358. Ohsaka Y, Tokumitsu Y, Nomura Y. Suppression of insulin-stimulated phosphatidylinositol 3-kinase activity by the D3-adrenoceptor agonist CL316243 in rat adipocytes. Growth Regul 1997;402:246-250.
359. Green A, Carroll RM, Dobias SB. Desensitization of D-adrenergic receptors in adipocytes causes increased insulin sensitivity of glucose transport. Am J Physiol 1996;271:E271-E276.
360. Widen E, Lehto M, Kanninen T, et al. Association of a polymorphism in the D3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. . Engl J Med 1995;333:348-351.
361. Umekawa T, Yoshida T, Sakane N, et al. Trp64Arg mutation of D3-adrenoceptor gene deteriorates lipolysis induced by D3-adrenoceptor agonist in human omental adipocytes. Diabetes 1999;48:117-120.
362. Wiesner TD, Bluher M, Windgassen M, et al. Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma. . Clin Endocrinol Metab 2003;88:3632-3636.
363. Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology 1999;70:460-465.
364. Niklasson M, Holmang A, Lonnroth P. Induction of rat muscle insulin resistance by epinephrine is accompanied by increased interstitial glucose and lactate concentrations. Diabetologia 1998;41:1467-1473.
365. Bessey PQ, Brooks DC, Black PR, et al. Epinephrine acutely mediates skeletal muscle insulin resistance. Surgery 1983;94:172-179.
366. Hansen I, Tsalikian E, Beaufrere B, et al. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin Am J Physiol 1986;250(3 Pt 1): E269-E273.
367. Clemmons DR. Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly [review]. Pituitary 2002;5: 181-183.
368. Wasada T, Aoki K, Sato A, et al. Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy. Endocr J 1997;44:617-620.
369. Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 2002;12:418-424.
370. Breidert M, Pinzer T, Wildbrett J, et al. Long-term effect of octreotide in acromegaly on insulin resistance. Horm Metab Res 1995;27:226-230.
371. Obici S, Rossetti L. Minireview: nutrient sensing and the regulation of insulin action and energy balance. Endocrinology 2003;144:5172-5178.
372. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity [review]. Diabetes Care 1990;13:610-630.
373. Leslie RD, Taylor R, Pozzilli P. The role of insulin resistance in the natural history of type 1 diabetes. Diabet Med 1997;14:327-331.
374. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992;13:415-431.
375. Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. . Clin Invest 1987;79:1510-1515.
376. Kahn BB, Shulman GI, DeFronzo RA, et al. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. . Clin Invest 1991;87:561-570.
377. Krook A, Kawano Y, Song XM, et al. Improved glucose tolerance restores insulin-stimulated AKT kinase activity and glucose transport in skeletal muscle from diabetic Goto-Kakizaki (GK) rats. Diabetes 1997;46:2110-2114.
378. Song XM, Kawano Y, Krook A, et al. Muscle fiber-type specific defects in insulin signal transduction to glucose transport in diabetic Goto-Kakizaki rats. Diabetes 1999;48:664-670.
379. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. . Biol Chem 1991;266:4706-4712.
380. Nelson BA, Robinson KA, Buse MG. High glucose and glucosamine induce insulin resistance via different mechanisms in 3T3-L1 adipocytes. Diabetes 2000;9:981-991.
381. Rossetti L, Hawkins M, Chen W, et al. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. . Clin Invest 1995;96:132-140.
382. Hawkins M, Barzilai N, Liu R, et al. Role of the glucosamine pathway in fatinduced insulin resistance. . Clin Invest 1997;99:2173-2182.
383. Hawkins M, Angelov I, Liu R, et al. The tissue concentration of UDP-Nacetylglucosamine modulates the stimulatory effect of insulin on skeletal muscle glucose uptake. . Biol Chem 1997;272:4889-4895.
384. Gazdag AC, Wetter TJ, Davidson RT, et al. Lower calorie intake enhances muscle insulin action and reduces hexosamine levels. Am J Physiol Regul Integr Comp Physiol 2000;278:R504-R512.
385. Wang J, Obici S, Morgan K, et al. Overfeeding rapidly induces leptin and insulin resistance. Diabetes 2001;50:2786-2791.
386. Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001;291:2376-2378.
387. Hart GW. Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. Annu Rev Biochem 1997;66:315-335.
388. Obici S, Rossetti L. Minireview: nutrient sensing and the regulation of insulin action and energy balance. Endocrinology 2003;144:5172-5178.
389. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating desensitization of the glucose transport system: role of hexosamine biosynthesis in the induction of insulin resistance. . Biol Chem 1991;266:4706-4712.
390. Marshall S, Bacote V, Traxinger RR. Complete inhibition of glucose-induced desensitization of the glucose transport system by inhibitors of mRNA synthesis. Evidence for rapid turnover of glutamine:fructose-6-phosphate amidotransferase. . Biol Chem 1991;266:10155-10161.
391. Cooksey RC, McClain DA. Transgenic mice overexpressing the rate-limiting enzyme for hexosamine synthesis in skeletal muscle or adipose tissue exhibit total body insulin resistance. Ann N Y Acad Sci 2002;967:102-111.
392. Cooksey RC, Hebert LF Jr, Zhu JH, et al. Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione. Endocrinology 1999;140:1151-1157.
393. Hawkins M, Hu M, Yu J, et al. Discordant effects of glucosamine on insulinstimulated glucose metabolism and phosphatidylinositol 3-kinase activity. . Biol Chem 1999;274:31312-31319.
394. Wells L, Vosseller K, Hart GW. A role for N-acetylglucosamine as a nutrient sensor and mediator of insulin resistance. Cell Mol Life Sci 2003;60:222-228.
395. Parker GJ, Lund KC, Taylor RP, et al. Insulin resistance of glycogen synthase mediated by o-linked N-acetylglucosamine. . Biol Chem 2003;278:10022-10027.
396. Chen KS, Heydrick SJ, Brown ML, et al. Insulin increases a biochemically distinct pool of diacylglycerol in the rat soleus muscle. Am J Physiol 1994;266: E479-E485.
397. Haring HU, Tippner S, Kellner M, et al. Modulation of insulin receptor signaling. Potential mechanisms of a cross talk between bradykinin and the insulin receptor [review]. Diabetes 1996;45[Suppl 1]:S115-S119.
398. Goldberg HJ, Whiteside CI, Fantus IG. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-beta I and -delta. . Biol Chem 2002;277: 33833-33841.
399. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000;97:12222-12226.
400. Reaven GM, Hollenbeck C, Jeng C-Y, et al. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24h in patients with NIDDM. Diabetes 1988;37:1020-1024.
401. Arslanian SA, Kahlan SC. Correlations between fatty acid and glucose metabolism. Diabetes 1994;43:908-914.
402. Felber JP, Ferrannini E, Golay A. Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes 1987;36:1341-1350.
403. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-789.
404. Randle PJ, Garland PB, Newsholme EA, et al. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann N Y Acad Sci 1965;131: 324-333.
405. Boden G, Jadali F, White J, et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. . Clin Invest 1991;88:960-966.
406. Boden G, Chen X, Ruiz J, et al. Mechanisms of fatty acid-induced inhibition of glucose uptake. . Clin Invest 1994;93:2438-2446.
407. Kelley D, Mokan M, Simoneau J-A, et al. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. . Clin Invest 1993;92: 91-98.
408. Roden M, Price T, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. . Clin Invest 1996;97:2859-2865.
409. Shulman GI. Cellular mechanisms of insulin resistance. . Clin Invest 2000;106: 171-176.
410. Yu C, Chen Y, Cline GW, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. . Biol Chem 2002;277:50230-50236.
411. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C and alterations in the insulin signaling cascade. Diabetes 1999;48:1270-1274.
412. Chalkley SM, Hettiarachchi M, Chisholm DJ, et al. Five-hour fatty acid elevation increases muscle lipids and impairs glycogen synthesis in the rat. Metabolism 1998;47:1121-1126.
413. Schmitz-Peiffer C, Browne CL, Oakes ND, et al. Alterations in the expression and cellular localization of protein kinase C isozymes epsilon and theta are associated with insulin resistance in skeletal muscle of the high-fat-fed rats. Diabetes 1997;46:169-178.
414. Itani SI, Ruderman NB, Schmieder F, et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and I kappa B-alpha. Diabetes 2002;51:2005-2011.
415. Kim YB, Shulman GI, Kahn BB. Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda/zeta but not on glycogen synthase kinase-3. . Biol Chem 2002;277:32915-32922.
416. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. . Clin Invest 2001;108:437-446.
417. Williamson RT, Lond MD. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. BMJ 1901;1:760-762.
418. Hawkins M, Barzilai N, Liu R, et al. Role of the glucosamine pathway in fatinduced insulin resistance. . Clin Invest 1997;99:2173-2182.
419. Patti ME. Nutrient modulation of cellular insulin action. Ann N Y Acad Sci 1999;892:187-203.
420. Randle PJ, Kerbey AL, Espinal J. Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diabetes Metab Rev 1988;4:623-638.
421. Liu Y, Uyeda K. A mechanism for fatty acid inhibition of glucose utilization in liver. Role of xylulose-5-P. . Biol Chem 1996;271:8824-8830.
422. Weigert C, Klopfer K, Kausch C. Palmitate-induced activation of the hexosamine pathway in human myotubes: increased expression of glutamine: fructose-6-phosphate aminotransferase. Diabetes 2003;52:650-656.
423. Williamson JR, Kreisberg RA, Felts PW. Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. Proc Natl Acad Sci U S A 1966;6:247-254.
424. Williamson J, Browning E, Scholz R. Control mechanisms of gluconeogenesis and ketogenesis. . Biol Chem 1969;250:4607-4616.
425. Antras-Ferry J, Le Bigot G, Robin P, et al. Stimulation of phosphoenolpyruvate carboxykinase gene expression by fatty acids. Biochem Biophys Res Commun 1994;203:385-391.
426. Oakes ND, Cooney GJ, Camilleri S, et al. Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 1997;46: 1768-1774.
427. Massillon D, Barzilai N, Hawkins M, et al. Induction of hepatic glucose-6-phosphatase gene expression by lipid infusion. Diabetes 1997;46:153-157.
428. Rodriguez JC, Gil-Gomez G, Hegardt FG, et al. Peroxisome proliferatoractivator receptor mediates induction of the mitochondrial 3-hydroxy-3-methyl-glutaryl-CoA synthase gene by fatty acids. . Biol Chem 1994;269: 18767-18772.
429. Rudich A, Kozlovsky N, Potashnik R, et al. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol 1997;272(5 Pt 1): E935-E940.
430. Tirosh A, Rudich A, Potashnik R, et al. Oxidative stress impairs insulin but not platelet-derived growth factor signalling in 3T3-L1 adipocytes. Biochem J 2001;355(Pt 3):757-763.
431. Rudich A, Tirosh A, Potashnik R, et al. Lipoic acid protects against oxidative stress induced impairment in insulin stimulation of protein kinase B and glucose transport in 3T3-L1 adipocytes. Diabetologia 1999;42:949-957.
432. Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002;23:599-622.
433. Talior I, Yarkoni M, Bashan N, et al. Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulinresistant mice. Am J Physiol Endocrinol Metab 2003;285:E295-E302.
434. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-790.
435. Ferrannini E, Natali A, Capaldo B, et al. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity: European Group for the Study of Insulin Resistance (EGIR). Hypertension 1997;30:1144-1149.
436. Rosenbloom AL, Kappy MS, DeBusk FL, et al. Progeria: insulin resistance and hyperglycemia. . Pediatr 1983;102:400-402.
437. Cefalu WT, Wang ZQ, Werbel S, et al. Contribution of visceral fat mass to the insulin resistance of aging. Metabolism 1995;44:954-959.
438. Shimokata H, Tobin JD, Muller DC, et al. Studies in the distribution of body fat. I. Effects of age, sex, and obesity. . Gerontol 1989;44:M66-M73.
439. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003;300:1140-1142.
440. Heilbronn LK, Ravussin E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am J Clin Nutr 2003;78: 361-369.
441. Barzilai N, Banerjee S, Hawkins M, et al. Caloric restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat. . Clin Invest 1998; 101:1353-1361.
442. Gabriely I, Ma XH, Yang XM, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 2002;51:2951-2958.
443. Ma XH, Muzumdar R, Yang XM, et al. Aging is associated with resistance to effects of leptin on fat distribution and insulin action. . Gerontol A Biol Sci Med Sci 2002;57:B225-B231.
444. Gabriely I, Ma XH, Yang XM, et al. Leptin resistance during aging is independent of fat mass. Diabetes 2002;51:1016-1021.